NICE recommends interim funding for Lilly’s breast cancer drugFinal draft guidance from NICE has recommended interim NHS funding for Eli Lilly’s Verzenios (abemaciclib) with fulvestrant, giving Share XNICE recommends interim funding for Lilly’s breast cancer drughttps://pharmaphorum.com/news/nice-recommends-interim-funding-for-lillys-breast-cancer-drug/
AZ’s selumetinib for rare disease gets FDA breakthrough statusAstraZeneca and Merck & Co/MSD’s selumetinib has been given a breakthrough designation from the US FDA for a Share XAZ’s selumetinib for rare disease gets FDA breakthrough statushttps://pharmaphorum.com/news/azs-selumetinib-rare-disease-fda/
Celgene-BMS merger looks good to go as shareholder backs downBristol-Myers Squibb’s mega-merger with Celgene looks set to go ahead after activist hedge fund Starboard Value backed out Share XCelgene-BMS merger looks good to go as shareholder backs downhttps://pharmaphorum.com/news/celgene-bms-merger-looks-good-to-go-as-shareholder-backs-down/
AZ signs multi-billion cancer R&D deal with Daiichi SankyoAstraZeneca is to raise $3.5 billion to fund a global development and marketing collaboration with Daiichi Sankyo, for Share XAZ signs multi-billion cancer R&D deal with Daiichi Sankyohttps://pharmaphorum.com/news/az-signs-multi-billion-cancer-rd-deal-with-daiichi-sankyo/
AZ gets NICE nod for ‘big advance’ Imfinzi in lung cancerAstraZeneca has won the backing of NICE for its cancer immunotherapy Imfinzi for non-small cell lung cancer (NSCLC), Share XAZ gets NICE nod for ‘big advance’ Imfinzi in lung cancerhttps://pharmaphorum.com/news/az-gets-nice-nod-for-big-advance-imfinzi-in-lung-cancer/
GSK mulls filings for multiple myeloma drugGlaxoSmithKline has announced more data making the case for its multiple myeloma antibody-drug conjugate GSK2857916, confirming that almost Share XGSK mulls filings for multiple myeloma drughttps://pharmaphorum.com/news/gsk-mulls-filings-for-multiple-myeloma-drug/
AI drug R&D company Exscientia signs deal with CelgeneUK artificial intelligence (AI) drug discovery company Exscientia has agreed a three year drug discovery deal with Celgene, Share XAI drug R&D company Exscientia signs deal with Celgenehttps://pharmaphorum.com/news/ai-drug-rd-company-exscientia-signs-deal-with-celgene/
Merck and Pfizer stop third Bavencio ovarian cancer trialMerck and Pfizer are discontinuing the Phase III JAVELIN Ovarian PARP 100 study evaluating Bavencio (avelumab) in advanced Share XMerck and Pfizer stop third Bavencio ovarian cancer trialhttps://pharmaphorum.com/news/merck-and-pfizer-stop-third-bavencio-ovarian-cancer-trial/
Question marks over AbbVie/Roche’s venetoclax after safety scareAbbVie and Roche have stopped recruiting patients for all multiple myeloma trials involving the drug venetoclax after a Share XQuestion marks over AbbVie/Roche’s venetoclax after safety scarehttps://pharmaphorum.com/news/question-marks-over-abbvie-roches-venetoclax-after-aml-safety-scare/
Roche’s Tecentriq gains new US lung cancer indicationRoche’s Tecentriq (atezolizumab) cancer immunotherapy has gained a new indication in the US, after the FDA granted it Share XRoche’s Tecentriq gains new US lung cancer indicationhttps://pharmaphorum.com/news/roches-tecentriq-gains-new-us-lung-cancer-indication/
Celgene gets US patent let-off ahead of BMS mergerShares in Celgene ticked up yesterday after a let-off in a US court case challenging the patents on Share XCelgene gets US patent let-off ahead of BMS mergerhttps://pharmaphorum.com/news/celgene-gets-us-patent-let-off-ahead-of-bms-merger/
Keytruda bags another EU approval in frontline lung cancerMerck & Co/MSD has tightened its hold on the first-line lung cancer market with another EU approval for Share XKeytruda bags another EU approval in frontline lung cancerhttps://pharmaphorum.com/news/keytruda-eu-approval-lung-cancer/
UK gets early access to Roche’s breast cancer immunotherapyHard on the heels of an FDA approval for Roche’s Tecentriq and Celgene’s Abraxane for triple-negative breast cancer Share XUK gets early access to Roche’s breast cancer immunotherapyhttps://pharmaphorum.com/news/uk-early-access-roches-breast-cancer-immunotherapy/
Lilly’s Cyramza hits mark in first-line lung cancer trialEli Lilly has produced phase 3 data that supports use of its Cyramza combined with Roche’s Tarceva in Share XLilly’s Cyramza hits mark in first-line lung cancer trialhttps://pharmaphorum.com/news/lillys-cyramza-hits-mark-in-first-line-lung-cancer-trial/
AZ joins with Seres to research role of gut microbiome in cancerAstraZeneca has announced an immuno-oncology collaboration with US biotech Seres Therapeutics, which will focus on increasing understanding of Share XAZ joins with Seres to research role of gut microbiome in cancerhttps://pharmaphorum.com/news/az-joins-with-seres-to-research-role-of-gut-microbiome-in-cancer/
